News | August 11, 2021
Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Deal signed with AOP Orphan for US commercial rights
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
The company has already embarked upon significant expansion in Turkey
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
Subscribe To Our Newsletter & Stay Updated
